FUB-JWH-018: Difference between revisions
Appearance
Content deleted Content added
No edit summary |
Importing Wikidata short description: "Chemical compound" (Shortdesc helper) |
||
(15 intermediate revisions by 11 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| IUPAC_name = (1-(4- |
| IUPAC_name = (1-(4-Fluorobenzyl)-1''H''-indol-3-yl)(naphthalen-1-yl)methanone |
||
| image = FUB-JWH-018_structure.png |
| image = FUB-JWH-018_structure.png |
||
| width = 150 |
|||
<!--Clinical data--> |
<!--Clinical data--> |
||
Line 9: | Line 11: | ||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_AU = |
| legal_AU = |
||
| legal_CA = |
| legal_CA = Schedule II |
||
| |
| legal_DE = NpSG |
||
| |
| legal_UK = Class B |
||
| legal_US = Schedule I |
|||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
Line 23: | Line 26: | ||
<!--Identifiers--> |
<!--Identifiers--> |
||
| CAS_number_Ref = |
| CAS_number_Ref = {{cascite|correct|CAS}} |
||
| CAS_number = |
| CAS_number = 2365471-45-8 |
||
| ATC_prefix = |
| ATC_prefix = |
||
| ATC_suffix = |
| ATC_suffix = |
||
| PubChem = |
| PubChem = |
||
| ChemSpiderID |
| ChemSpiderID = 34450892 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
⚫ | |||
| UNII = U0Z5KO073G |
|||
| InChI = |
|||
| InChIKey = |
|||
⚫ | |||
⚫ | |||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=26 | H=18 | N=1 | O=1 | F=1 |
| C=26 | H=18 | N=1 | O=1 | F=1 |
||
⚫ | |||
| molecular_weight = 379.43 g/mol |
|||
⚫ | |||
⚫ | |||
}} |
}} |
||
'''FUB-JWH-018''' (also known as '''FUB-018''') is |
'''FUB-JWH-018''' (also known as '''FUB-018''') is a [[naphthoylindole]]-based [[synthetic cannabinoid]], representing a molecular hybrid of [[JWH-018]] and [[AB-FUBICA]] or [[ADB-FUBICA]].<ref>{{cite web | url=https://www.caymanchem.com/app/template/Product.vm/catalog/17332 | title=FUB-JWH 018 | publisher=Cayman Chemical | access-date=8 July 2015}}</ref><ref>{{cite journal | title=Apport d'un spectromètre UHPLC-HR-Q-TOF pour l'identification des nouvelles substances psychoactives en circulation | vauthors = Lamoureux C | journal=Toxicologie Analytique et Clinique | date=June 2015 | volume=27 | issue=2 | pages=S67 | doi=10.1016/j.toxac.2015.03.107}}</ref> |
||
==Legal |
==Legal status== |
||
In the United States, all CB<sub>1</sub> receptor agonists of the 3-(1-naphthoyl)indole class such as FUB-JWH-018 are [[Schedule I Controlled Substance]]s.<ref>{{UnitedStatesCode2|21|812|Schedules of controlled substances}}</ref> |
|||
As of October 2015 FUB-JWH-018 is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language= |
As of October 2015 FUB-JWH-018 is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=zh | access-date=1 October 2015 | archive-date=1 October 2015 | archive-url=https://web.archive.org/web/20151001222554/http://www.sfda.gov.cn/WS01/CL0056/130753.html | url-status=dead }}</ref> |
||
==See also== |
==See also== |
||
Line 50: | Line 53: | ||
* [[ADB-FUBINACA]] |
* [[ADB-FUBINACA]] |
||
* [[AMB-FUBINACA]] |
* [[AMB-FUBINACA]] |
||
⚫ | |||
* [[FUB-144]] |
* [[FUB-144]] |
||
* [[FUB-APINACA]] |
* [[FUB-APINACA]] |
||
⚫ | |||
* [[FDU-PB-22]] |
* [[FDU-PB-22]] |
||
* [[FUB-PB-22]] |
* [[FUB-PB-22]] |
||
Line 64: | Line 67: | ||
{{Cannabinoidergics}} |
{{Cannabinoidergics}} |
||
[[Category:Cannabinoids]] |
|||
[[Category:Designer drugs]] |
[[Category:Designer drugs]] |
||
[[Category:Naphthoylindoles]] |
[[Category:Naphthoylindoles]] |
Revision as of 10:48, 23 April 2022
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C26H18FNO |
Molar mass | 379.434 g·mol−1 |
3D model (JSmol) | |
| |
|
FUB-JWH-018 (also known as FUB-018) is a naphthoylindole-based synthetic cannabinoid, representing a molecular hybrid of JWH-018 and AB-FUBICA or ADB-FUBICA.[1][2]
Legal status
In the United States, all CB1 receptor agonists of the 3-(1-naphthoyl)indole class such as FUB-JWH-018 are Schedule I Controlled Substances.[3]
As of October 2015 FUB-JWH-018 is a controlled substance in China.[4]
See also
- AB-FUBINACA
- ADB-FUBINACA
- AMB-FUBINACA
- CHM-018
- FUB-144
- FUB-APINACA
- FDU-PB-22
- FUB-PB-22
- MDMB-FUBICA
- MDMB-FUBINACA
References
- ^ "FUB-JWH 018". Cayman Chemical. Retrieved 8 July 2015.
- ^ Lamoureux C (June 2015). "Apport d'un spectromètre UHPLC-HR-Q-TOF pour l'identification des nouvelles substances psychoactives en circulation". Toxicologie Analytique et Clinique. 27 (2): S67. doi:10.1016/j.toxac.2015.03.107.
- ^ : Schedules of controlled substances
- ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.